Nguyen Bao-Ngoc, Neville Richard F, Abugideiri Mustafa, Amdur Richard, Sidawy Anton N
Department of Surgery, George Washington University, Washington, D.C..
Department of Surgery, George Washington University, Washington, D.C.
J Vasc Surg. 2014 Apr;59(4):1003-8. doi: 10.1016/j.jvs.2013.10.091. Epub 2013 Dec 19.
Despite advances in endovascular techniques, infrapopliteal bypasses are still required for limb salvage. Short-term graft patency is an important outcome parameter reflecting technical considerations and acute graft thrombosis. Both are important prerequisites for long-term patency. In this analysis, we compared the 30-day patency of all conduit configurations for infrapopliteal bypasses.
All primary infrapopliteal bypasses from the American College of Surgeons-National Surgical Quality Improvement Program database between 2005 and 2010 were divided into six groups: (1) great saphenous vein (GSV); (2) prosthetic conduit (prosthetic); (3) prosthetic conduit with a distal anastomotic venous adjunct (ADJ), such as a cuff or patch (prosthetic + ADJ); (4) composite graft of prosthetic and a vein segment (composite); (5) spliced autogenous vein (spliced vein); and (6) arm vein. Thirty-day graft failure, patient demographics, and operative details were compared among groups. A multivariate model was used for statistical analysis.
A total of 5375 infrapopliteal bypasses were analyzed by conduit: GSV, 3983 (75%); prosthetic, 898 (17%); spliced vein, 160 (3%); prosthetic + ADJ, 112 (2%); arm vein, 93 (2%); and composite, 91 (2%). The difference among groups in demographics and comorbidities was not statistically significant. Perioperative mortality rates were similar among different conduits. After adjusting for sex, age, weight, race, and previous cardiac surgery, the bypass conduit had a significant independent association with 30-day graft patency (P = .006). The GSV failure rate was 7.5%. Composite had a significantly higher 30-day failure rate (15.4%, P = .006). There was no significant difference in 30-day failure rate of spliced vein (5.6%, P = .37) or arm vein (4.3%, P = .24) conduits compared with GSV. Prosthetic had significantly higher 30-day failure rate than GSV (10.5%, P = .004). The addition of adjuvant venous tissue at the distal anastomosis of prosthetic bypasses did not significantly improve their 30-day patency (failure rate of 9.8% for prosthetic + ADJ and 10.5% for prosthetic). There was no significant difference in graft patency between alternative venous conduits (arm vein/spliced vein) and prosthetic + ADJ.
Venous conduits (GSV, spliced vein, arm vein) deliver the best 30-day patency for infrapopliteal bypasses, and GSV remains the most commonly used graft. Prosthetic grafts had a higher 30-day failure rate. Composite grafts should be abandoned because their early patency is not better than pure prosthetic conduits. The addition of a distal venous adjunct did not seem to improve acute prosthetic graft patency, which may reflect lack of effect on thrombogenicity rather than the myointimal hyperplastic response that effects long-term failure of infrapopliteal bypass.
尽管血管内技术不断进步,但为挽救肢体仍需进行腘以下动脉旁路移植术。短期移植物通畅率是反映技术考量和急性移植物血栓形成的重要结果参数。这两者都是长期通畅的重要前提条件。在本分析中,我们比较了腘以下动脉旁路移植术所有导管配置的30天通畅率。
将2005年至2010年间美国外科医师学会-国家外科质量改进计划数据库中的所有原发性腘以下动脉旁路移植术分为六组:(1)大隐静脉(GSV);(2)人工血管;(3)带有远端吻合静脉辅助装置(ADJ)的人工血管,如袖套或补片(人工血管+ADJ);(4)人工血管与静脉段的复合移植物(复合移植物);(5)拼接自体静脉(拼接静脉);(6)上臂静脉。比较各组的30天移植物失败情况、患者人口统计学特征和手术细节。采用多变量模型进行统计分析。
共分析了5375例腘以下动脉旁路移植术的导管情况:GSV 3983例(75%);人工血管898例(17%);拼接静脉160例(3%);人工血管+ADJ 112例(2%);上臂静脉93例(2%);复合移植物91例(2%)。各组在人口统计学特征和合并症方面的差异无统计学意义。不同导管的围手术期死亡率相似。在对性别、年龄、体重、种族和既往心脏手术进行校正后,旁路移植导管与30天移植物通畅率有显著的独立相关性(P = 0.006)。GSV的失败率为7.5%。复合移植物的30天失败率显著更高(15.4%,P = 0.006)。与GSV相比,拼接静脉(5.6%,P = 0.37)或上臂静脉(4.3%,P = 0.24)导管的30天失败率无显著差异。人工血管的30天失败率显著高于GSV(10.5%,P = 0.004)。在人工血管旁路移植术的远端吻合处添加辅助静脉组织并不能显著改善其30天通畅率(人工血管+ADJ的失败率为9.8%,人工血管为10.5%)。替代静脉导管(上臂静脉/拼接静脉)与人工血管+ADJ之间的移植物通畅率无显著差异。
静脉导管(GSV、拼接静脉、上臂静脉)在腘以下动脉旁路移植术中的30天通畅率最佳,且GSV仍是最常用的移植物。人工血管移植物的30天失败率更高。复合移植物应被摒弃,因为其早期通畅率并不优于单纯人工血管。在人工血管远端添加静脉辅助装置似乎并不能改善急性人工血管移植物通畅率,这可能反映出对血栓形成性缺乏影响,而非影响腘以下动脉旁路移植术长期失败的肌内膜增生反应。